The synthesis and biological evaluation of sixteen-membered macrolides possessing a 4-0-alkyl-a-L-cladinosyl moiety as a neutral sugar are described. These potent novel derivatives have been efficiently synthesized avoiding glycosylations. Two hydroxyl groups in mycarose of the tri- ( (Fig. 1) . As part of our program in this area, we have synthesized the 9-dehydro JAN. 1997 (a carbonyl group at the C-9 position) derivatives including compound (1) via glycosylations, and excellent metabolic stability of 1 was shown in rat plasma in vitro5). Recently, we have also prepared the 9-OH
Sixteen-membered macrolide antibioticsX) are safe and useful in treating infections caused by Gram-positive bacteria and exert fewer interaction with other drugs and have less effect on the intestinal tract in comparison with the fourteen-membered macrolides. There seems to be some possibilities that their pharmacokinetics2) and therapeutic effects will be improved with chemical modifications. Kirst proposed several important factors for the improvement of macrolide antibiotics3). Our work was focused on following two elements; 1) the improvement of chemical and metabolic stability, and 2) the improvementof serum concentrations. One explanation for the poor pharmacokinetics involves in vivo deacylation4) at the neutral sugar moiety, which led us to design, synthesize and study of several stages of 4-0-alkyl-L-cladinose analogues ( Fig. 1 ). As part of our program in this area, we have synthesized the 9-dehydro JAN. 1997 (a carbonyl group at the C-9 position) derivatives including compound (1) via glycosylations, and excellent metabolic stability of 1 was shown in rat plasma in vitro5). Recently, we have also prepared the 9-OH derivatives, such as compound (2) , using bioconversion, and dramatic improvement of pharmacokinetics was demonstrated6*.
Sakakibara and Omura et al. have investigated many 3-OH derivatives of leucomycin, including rokitamycin (RKM), which is a very effective semi-synthetic sixteen-membered macrolide antibiot-
In this paper, we wish to report the efficient synthesis of 3-OH derivatives ( Fig. 1) , such as compound (3f)t>9), a 4-O-alkyl-L-cladinose analogue of leucomycin V10) (LM-V) (Fig. 2) , without glycosylation or biotransformation. The reported compound (3f) exhibited not only potent antibacterial activities in vitro but also * A compound (3f) was originally prepared via glycosylation and biotransformations. See ref. 9 . The preparation of 3f using byconversion will be reported elsewhere. excellent pharmacokinetics in spite of its 3-OHstructure.
Structure activity relationships (SAR) between the neutral sugars and antibacterial activities were also discussed.
When Sano, spiramycin I, a chemically stabilized silyl ether intermediate was used1 1'-12*. Because there seemed to be some difficulties in introducing general alkyl groups**'13* to hydroxyl groups of the neutral sugar moiety in leucomycins, 3, 18-(0-silyl)acetal protection could be desired. 4"-0-Methylation of erythromycin, however, has been already reported14*.
On the other hand, introducing a methyl group onto the tertiary hydroxyl group at C-3" position of a sixteen-membered macrolide antibiotic could be only done via glycosylation of a neutral sugar5'15*. It is mainly because the 3"-hydroxyl group seems to be highly hindered sterically in addition to its low reactivity12*, that conversion of 3"-OH to 3"-OCH3 has not been reported. Chemistry
The ter/-butyldimethylsilyl (TBS) protection of leucomycin A7m' 16* (LM-A7) afforded tris-TBS ether (4) in a good yield. Selection of heterogeneous basic hydrolysis resulted in a quantitative chemoselective saponification at the C-4" position to generate diol (5) . Fortunately, these conditions using phase transfer catalyst did not affect the lactone bond with a fused seven-membered silyl acetal ring.
Chemoselective 4"-O-alkylations were completed under rather strong conditions to afford the mono alkyl n Some reactive alkylation (i.e. methoxymethyl or benzyl) did not require 3,18-(0-silyl) THE JOURNAL OF ANTIBIOTICS derivatives, compounds (6b~6g). A methyl group was then introduced at the tertiary hydroxyl group at the C-3" position (Scheme 1). First, direct methylation of 6 gave poor results because of the presence of a free dimethylamino group. Thus, an TV-oxide intermediate of the dimethylamino group was used as follows: Oxidation of the dimethylamino group of 6 with mCPBAgave unstable TV-oxides, compounds (7b~7g), quantitatively. Without purification at this stage, subsequent methylation exclusively proceeded at the 3"-alcohol to form 4-O-alkyl-L-cladinose moiety as a neutral sugar, accompanied with slight decomposition. In the case of introducing two methyl groups, the dimethylamino group of 5 was oxidized followed by dimethylation to give the compound (8a).
Fully protected unstable intermediates (8a~8g) were successively treated with gently acidic conditions (i.e. silica gel or diluted hydrochloric acid) to generate the free dimethylamino alcohol of the mycaminose moiety. Evidence of structure on compound (9f) was demonstrated by acetylation of 9f without any additional base to give its 2'-0-acetyl derivative (10) in a quantitative yield. Finally, deprotection of two TBS groups with exact 2.0m of TBAF completed titled compounds (3a~3g) via acidic workups (see experimental). The above mentioned useful deprotection (compound(8) to (9) ) could be observed in other substrates also. When unstable 2'-0-TBS midecamycin A3 iV-oxide (ll) (Fig.  3 ) was treated with a mild acidic condition, midecamycin A3 (a free dimethylamino alcohol) was mainly recovered as expected. Structures of these resulting antibiotic analogues (3a~3g) and (20-22) were confirmed by^H NMR spectra (see experimental). The compounds (3f, 3g) were fully identified with those prepared via glycosylation and biotransformations previously9). The structure of the resulted neutral sugar was confirmed by acid hydrolysis. For example, treatment of 3f with /7-toluenesulfonic acid and ethanol smoothly gave ethyl 4-0-(3-methylbutyl)-/?-L-cladinoside5) with trace of its a-anomer.
Biological Evaluation The antibacterial activities in vitro of novel 4-0-alkyla-L-cladinosyl derivatives (3a-3g) and the structurally related analogues (20 -22), compared with corresponding antibiotics which possess a free hydroxyl group at the C-3 position, are shown in Table 1 . In the class of cladinose analogues , the activities of selected novel derivatives with suitable alkyl chain length (C3 -C5 and benzyl) were clearly improved based on that of Table 1 . Antibacterial activities of leucomycin derivatives and LM-A7(MIC, A*g/ml). JAN. 1997 after 200 mg/kg oral administration are shown in Fig. 5 . A time course pattern of 3f was very close to that of RKM, however, absolute concentrations of 3f were clearly higher than that of RKM. A serum level of LM-A7was less than RKM, undoubtedly (data not shown). The maximumconcentration of 3f in serum was comparable to that of clarithromycin (CAM)17) despite the free C-3 hydroxyl group of compound (3f). These excellent results led us to clarify further pharmacokinetic study of 3f using hamsters as rather large test animals. In the field of sixteen-membered macrolides, pharmacokinetics are sometimes strongly affected with animal species7). Fig. 6 shows concentrations of antibiotics in serum of hamsters after 500 mg/kg oral administration. The maximumconcentration of 3f is higher than that of RKMor CAM.
Extremely high efficacy of synthesized 3f in vivo may be promising with both its potent antibacterial activities in vitro and its splendidly high serum concentrations in vivo. The described chemistry is efficient considering the 
Pharmacokinetics (Serum Level) Tests in Mice In Vivo
A test compoundwas mixed with a 0.2% aqueous solution of CMCto give a concentration of 4.0mg/ml and a 1.0 ml portion of the resulting emulsion was orally 37 administrated to 4 weeks old male Jcl : ICR mice. Blood was collected from armpit of the mice 0.5, 1, 2, 4 and 6 hours after the administration of the test compound (n=2). The collected blood was allowed to stand at 0°C for 2 hours and centrifuged at 3000rpm for 20 minutes to obtain serum. To the serum was added an equivalent volume of 50% CH3CN-0.05m phosphate buffer (pH 7.0). The resulting mixture served as a serum sample. The concentration of the test compound in the serum sample was measured by a bioassay method using M. luteus ATCC9341.
Pharmacokinetics (Serum Level) Tests in Hamsters
In Vivo
A test compoundwas mixed with a 0.2% aqueous solution of CMCto give a concentration of 40mg/ml and a 1.0ml portion of the resulting emulsion was orally administrated to 5 weeks old female Std : Syrian hamsters (ca. 80g body weight). Blood was collected from armpit of the hamsters 0.5, 1, 2 and 4 hours after the administration of the test compound(n= l). The collected blood was allowed to stand at 0°C for 2 hours and centrifuged at 3000rpm for 20 minutes to obtain serum. To the serum was added an equivalent volume of 50% CH3CN-0.05m phosphate buffer (pH 7.0). The resulting mixture served as a serum sample. The concentration of the test compound in the serum sample was measured by a bioassay method using M. luteus ATCC9341.
9, 1 8,2/-Tri-O-^rr-butyldimethylsilylleucomycin A7
3,18-Acetal (4) To 1.00g (1.32mmol) of leucomycin A7 was added dry DMF (12ml), and 1.18g (7.82mmol) of /-butyldimethylsilyl chloride and 1.08g (15.8mmol) of imidazole were added. The mixture was stirred at 50°C for 24 hours. The reaction mixture was cooled to room temperature, and CH3OH(50ml) was added followed by stirring at room temperature for 30 minutes. Evaporation gave a residue which was extracted with benzene (500ml) and the benzene layer was successively washed with saturated aqueous NaHCO3(500 ml) twice and brine (500ml) To a solution of6f (1.42g, 1.27mmol) in CHC13 (71 ml) was added mCPBA (328mg, 1.90mmol). After stirring at roomtemperature for 5 minutes, the solution was dropped into 10% aqueous Na2S2O3 (150ml) and extracted with CHC13(500ml). The organic layer was successively washed with saturated aqueous NaHCO3 (500 ml) twice and brine (500 ml) twice. Then, the organic layer was dried and concentrated to afford 1.42g of iV-oxide (7f). To a stirred mixture of crude 7f (1.42g) and oily sodium hydride (251 mg as 60%, 6.27mmol) in dry DMF (14ml) was added iodomethane (5.39g, 37.9mmol 
To a solution of 5 (200mg, 0.19mmol) in CHC13
(10ml) was added raCPBA (50mg, 0.28mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na2S2O3 (100ml) and extracted with CHC13(100ml). The organic layer was successively washed with saturated aqueous NaHCO3 (100 ml) twice and brine (100 ml) twice. Then, the organic layer was dried and concentrated to afford 200mgof
Af-oxide of 5. To a stirred mixture of this crude N- JAN. 1997 oxide (200mg) and oily sodium hydride (60mg as 60%, 1.5 mmol) in dry DMF(2.0ml) was added iodomethane (1.2g, 8.4mmol 6 .10 (1H, m, ll-H), 6.10 (1H, m, 12-H).
To a stirred solution of 9f (30mg, 0.03mmol) in dry CH3CN(0.90 ml) was added at room temperature acetic anhydride (6.0/4 0.06mmol). After stirring at 30°C for 16 hours, 1.0m NH4OH (0.90ml, 0.09mmol) was added to the resulting solution, which was allowed to stand at room temperature for 20 minutes. Evaporation gave a residue which was extracted with CHC13(30ml) and the organic layer was washedwith saturated aqueous NaHCO3 (30ml) and brine (30ml). This was concentrated and purified by preparative TLC[hexane -acetone 3//-O-Methyl-4"-O-(3-methylbutyl)leucomycin V (3f) To 1.07g (1.05mmol) of9fwas added 8.4ml ofa 2.0m solution of TBAFin THFand the mixture was allowed to react at 45°C for 1 hour. Then the reaction mixture was dropped into 5% aqueous KHSO4(50ml) and then extracted with CHC13(300ml) twice. The organic layers 
Reaction of 9a gave 3a in 54% yield by a similar procedure to 3f. 9, 18-Di-O-^r/-butyldimethylsilyl-3//-O-ethyl-4//-O-(3-methylbutyl)leucomycin V 3, 1 8-Acetal (17) To a stirred mixture of 6f (190mg, 0.17mmol) and oily sodium hydride (34mg as 60%, 0.85mmol) in dry DMF (1.0ml) was addediodoethane (796mg, 5.1 mmol). The resulting mixture was stirred at 45°C for 3 hours, then cooled to roomtemperature. After slowly adding H2O(100ml), the mixture was extracted with CHC13 (100ml) twice. The organic layers were combined and washed with brine (100 ml) twice, dried and concentrated to give 114mgof crude 12. To a solution of crude 12 in CHC13 (5.7ml) was added mCPBA (26mg, 0.15mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na2S2O3
(30ml) and extracted with CHC13(60ml (1H, dt, 13-H), 5.76(1H, dd, 10-H), 6.10 (1H, m, ll-H), 6.10 (1H, m, 12-H).
9, 1 8-Di-O-^r/-butyldimethylsilyl-4//-O-(3-methylbutyl)-3"-0-ft-propylleucomycin V 3, 1 8-Acetal (18) To a solution of 13 (147mg, 0.13mmol) in CHC13 (6.5ml) was added mCPBA(24mg, 0.14mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na2S2O3 (30ml) and extracted with CHC13(60ml). The organic layer was successively washed with saturated aqueous NaHCO3 (60ml) twice and brine (60ml) twice. Then, the organic layer was dried and concentrated to afford 155mgof crude 15. This oily product was charged on preparative TLC plates (Merck TLC 60F254). After allowing the plates stand for 3 days, and then development was carried out for purification ] to afford 60mg (0.06mmol, 41% overall 2 steps) of 18. 
